{"id":870,"date":"2013-01-09T10:59:00","date_gmt":"2013-01-09T10:59:00","guid":{"rendered":"\/?p=870"},"modified":"2013-03-25T20:14:46","modified_gmt":"2013-03-25T20:14:46","slug":"advaxis-inc-otcadxs-surges-40-in-value-upon-a-medical-presentation","status":"publish","type":"post","link":"\/articles\/advaxis-inc-otcadxs-surges-40-in-value-upon-a-medical-presentation\/","title":{"rendered":"Advaxis, Inc. (OTC:ADXS) Surges 40% In Value Upon a Medical Presentation"},"content":{"rendered":"

\"26ADXS_chart.png\"The shares of Advaxis, Inc. (OTC:ADXS<\/a>) soared 39% yesterday as the developer of next generation immunotherapies for life-threatening diseases announced its participation in an annual medical forum, giving no details whatsoever regarding what exactly will be presented. <\/p>\n

Closing trade at $0.0465 per share, ADXS<\/a> registered a 38.81% improvement over its previous close. Shifting in excess of 9.6 million shares, the stock set a new six-month high volume. Thus, ADXS<\/a> made a serious attempt to rally back to its late-November level when the stock was traded at $0.05-0.06 per share.<\/p>\n

Since the company provided no additional information about its Jan. 8 presentation, today’s market performance will hardly be affected by the former. To ensure sustainable chart growth however, ADXS<\/a> had better fix the great discrepancy between its total assets of $5.6 million and its current market cap of $18+ million. Unfortunately, this would rather be a mission impossible for the time being. See the figures for yourselves:<\/p>\n